How to read and use this page
This page is the detail of the medical field's "Technology Seeds (companies' manufacturing technologies)". It compiles what it is about along with related market and regulatory information. For first-time visitors, it explains how to read it and how to operate it.
The content listed
- Challenge: What you are struggling with (Technology overview)
- Market data: Production value of related medical devices, etc. (actual data from national official statistics).
- Situation and voices from the field: The likely state of the medical field and a brief voice (reference information generated automatically by AI).
- Solution hypothesis: Possible solution ideas (generated automatically by AI).
- Related Seeds: Similar themes
* Content generated by AI (voices from the field, solutions, etc.) is reference information. For final medical and regulatory decisions, always confirm with official sources or specialists.
View the how-to guide
Technology for presenting premium information only to specific visitors at online exhibitions
AI translated
- Cardiovascular
- Respiratory
- Gastroenterology
At online exhibitions, it is possible to present premium information only to visitors in specific categories, while presenting general information to other visitors. For example, when a medical device manufacturer exhibits online, a challenge arises where they want to present premium information about their products to doctors, but only want to present general information to competitors. By utilizing the patents held by our company, this challenge can be solved.
特許第7171116号
Related patents
These are patents that may be related to this Needs/technology. Sources: Japan Patent Office Patent Information Acquisition API / Google Patents.
The details of this solution could not be loaded. Check your connection and try again.
Needs × Solution Hypothesis
Assumed elemental technologies
Market for this solution (production value, official statistics)
Regulatory approval process flow (Japan, US, EU, ASEAN)
Highlights the class-classification guideline equivalent to "Class Ⅱ". Actual classification and pathway differ depending on the product's characteristics and each jurisdiction's regulations. Please always confirm with official information and experts.
JapanPMDA / Ministry of Health, Labour and Welfare
- General medical devices → Manufacturing/marketing notification
- Controlled medical device → third-party certification (with standards) / ministerial approval
- High-risk control → PMDA review → MHLW Minister approval
- High-risk control (high risk) → PMDA review → Minister approval
View required documents and items
- Approval application / STED (Summary Technical Documentation)
- Intended use & effect
- Shape, structure & principle
- Raw materials & ingredients
- Performance & specs
- Non-clinical testing (biological safety, electrical safety, EMC, performance, stability)
- Risk analysis (ISO 14971)
- Clinical trial results (when novelty is high)
- Manufacturing method & facility
- Documents on QMS conformity
- Package insert (draft)
QMS conformity inspection and marketing authorization required
United StatesFDA
- Class I → mostly Exempt (registration/listing).
- Class II → 510(k) / De Novo for novel devices.
- Class III → PMA (premarket approval)
- Class III equivalent → PMA
View required documents and items
- Grounds for equivalence (Predicate device) / substantial equivalence (510(k))
- Indications for Use
- Device Description
- Performance data (bench / animal)
- Biocompatibility
- Software documentation (if applicable)
- Sterilization and expiry period
- Labeling
- (De Novo) classification request & special controls
- (PMA) clinical trial data & manufacturing information
Facility registration, QMSR (quality), and, if needed, an IDE clinical trial
EuropeEU MDR (2017/745)
- Class I → self-declaration of conformity → CE mark
- Class IIa/IIb → Notified Body involvement → CE.
- Class III → NB (design review) → CE
- Class III → NB (high risk) → CE
View required documents and items
- Technical documentation (Annex II/III)
- General Safety and Performance Requirements (GSPR) checklist
- Risk management (ISO 14971)
- Design & manufacturing information
- Clinical Evaluation Report (CER)
- Post-market surveillance (PMS) plan & PMCF
- Labeling & IFU
- UDI / EUDAMED registration
- Declaration of Conformity (DoC)
Technical documentation, clinical evaluation, UDI & EUDAMED registration
ASEANAMDD (national authorities)
- Class A (low) → registration/notification
- Class B → CSDT submission/registration
- Class C → evaluation/registration
- Class D (high) → detailed evaluation/approval
View required documents and items
- CSDT (common submission format)
- Executive summary
- Essential Principles checklist
- Device description and specifications
- Design verification & validation
- Clinical evidence
- Risk management
- Labeling
- Manufacturer information & QMS (ISO 13485)
Apply to each country (Thailand / Malaysia / Singapore, etc.) using the CSDT format.
The flow of insurance listing and insurance points (Japan / Ministry of Health, Labour and Welfare, Chuikyo)
This is a guide to whether this device/technology can be calculated under existing insurance fee points, and to the flow for newly acquiring one if not. The actual category depends on Chuikyo's evaluation.
- ① Check whether it falls under existing fee points: If an equivalent already-listed material/technology exists, it is calculated under an existing category of designated insured medical materials (Category B) or under an existing technical fee (Category A = included in the technical fee).
- ② New acquisition for new functions/technologies: A function not in existing listings = Category C1 (new function) / involving new technology = Category C2 (new function and new technology).
- ③ Submit an insurance-application request (after regulatory approval) → assessed by the Chuikyo Specialized Organization for Insured Medical Materials.
- ④ Price calculation: Comparison with a similar functional category (compared against a similar already-listed product) / cost-accounting method.
- ⑤ Notification and listing: Insurance coverage begins at one of several listing opportunities held each year.
* Whether specific applicable fee points exist requires cross-checking against the "Medical Service Fee Schedule (designated insured medical materials, surgery/procedures)" (being addressed progressively).
Cautions at commercialization (advertising regulations)
These are the main points to note during commercialization and promotion, based on the Pharmaceuticals and Medical Devices Act and the Medical Advertising Guidelines. The applicable scope varies depending on the nature of the solution.
- ① Ban on advertising unapproved products (Article 68 of the Pharmaceuticals and Medical Devices Act): Before approval, certification, or notification, advertising that names a product and promotes its efficacy or performance is prohibited. Be careful with communications at the research stage.
- ② Ban on exaggerated advertising (Article 66 of the Pharmaceuticals and Medical Devices Act): Regarding efficacy, performance, and safety, expressions that are contrary to fact or exaggerated, and superlative expressions (unsubstantiated claims such as "best" or "No.1") are not allowed.
- ③ Promotion within the approved scope: The intended use and efficacy that can be claimed are limited to what is granted by the approval/certification. Do not promote off-label uses.
- ⑤ Regulatory differences by audience: The scope of advertising regulation differs for the general public versus healthcare professionals. Advertising by medical institutions must also follow the "Medical Advertising Guidelines" (restrictions on testimonials, before-and-after images, and comparative superiority advertising).
Source: Medical advertising regulations (MHLW) ↗ / PMD Act, Articles 66 and 68
Refer to similar approval review reports
Especially for higher-class medical devices and "new medical devices" (including cases where a Class II device was approved as a new medical device), the approval review reports of similar past devices are extremely useful for application strategy, evaluation items, and reviewing non-clinical/clinical data. You can search for the actual reports by the expected generic name below.
Search related clinical trials
Knowing what clinical trials and research are being conducted for similar solutions is useful for development planning, evidence design, and understanding competitors. You can search in Japan (jRCT / UMIN-CTR) and overseas (ClinicalTrials.gov).
On-site situation and voices (VOC)
Voices from the field